# US Prostate Cancer Treatment Market

> US Prostate Cancer Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), By Administration Route (Oral, Injection, Intravenous, Topical), By End Userss (Hospitals, Clinics, Homecare, Research Institutions) and By Disease Stage (Localized, Locally Advanced, Metastatic) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.21%
- **2024:** $ 2,181.64 Million
- **2025:** $ 2,295.3 Million
- **2035:** $ 3,814.9 Million
- **Key Players:** Astellas Pharma (JP), Bayer AG (DE), Johnson & Johnson (US), Pfizer Inc (US), Merck & Co (US), Novartis AG (CH), Sanofi (FR), Ipsen S.A. (FR)

**Report ID:** MRFR/MED/51014-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-prostate-cancer-treatment-market-52774

---

## Market Summary

## **US Prostate Cancer Treatment Market Overview**

As per MRFR analysis, the US Prostate Cancer Treatment Market Size was estimated at 2.29 (USD Billion) in 2023. The US Prostate Cancer Treatment Market Industry is expected to grow from 2.75(USD Billion) in 2024 to 4.2 (USD Billion) by 2035. The US Prostate Cancer Treatment Market CAGR (growth rate) is expected to be around 3.925% during the forecast period (2025 - 2035).

### **Key US Prostate Cancer Treatment Market Trends Highlighted**

The US Prostate Cancer Treatment Market is witnessing drastic trends from technology improvements and greater awareness regarding the existence of prostate cancer. The incidence of prostate cancer in men is one of the main contributing factors, especially for those over the age of 50. This has created a greater need for hormone therapy, surgery, and radiation oncology. There is also a strong market growth because of the demand for early treatment using better screening techniques like the Prostate Specific Antigen (PSA) test, as it allows treatment to be performed during more effective phases of the illness.

The development of tailored medicine and innovative medical treatments still have great potential. The move to precision medicine opens the door for tailored treatment based on a patient’s individual tumor’s genetics. This is a remarkable change that might amplify the patient’s results. There is abundant prostate cancer management research and product development opportunities due to AI taking over diagnosing tasks and preparing options. Other recent changes bolster the adoption of other procedures which require incisions as well. These minimally invasive techniques are quicker and have a more preferable side effect profile when compared with traditional approaches.

Surgical procedures using robotic arms are becoming increasingly popular in the United States as they allow surgeons to operate more accurately. Moreover, various forms of patient education and self-help materials are being provided which helps in improving adherence to treatment as well as therapy satisfaction. There is an increasing attention to comprehensive palliative care that also includes the relief of associated mental health issues, which broadens the treatment framework for prostate cancer in the US.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **US Prostate Cancer Treatment Market Drivers**

### **Increasing Incidence of Prostate Cancer**

The rising incidence of prostate cancer in the United States is a significant driver for the US Prostate Cancer Treatment Market Industry. According to the American Cancer Society, prostate cancer is the second most common cancer among men, with an estimated 268,490 new cases expected in 2022 alone. This increasing rate highlights the growing need for effective treatment options. Furthermore, the U.S. National Cancer Institute has reported a gradual rise in the incidence rate from 138 cases per 100,000 men in 2011 to approximately 155 in 2019, indicating a surge of about 12.3% over eight years.

Major organizations such as the American Urological Association are heavily involved in research efforts and treatment guidelines, which can further influence the market growth as they push for the development of new therapies, creating a favorable environment for industry players to engage and innovate in the landscape of prostate cancer treatment.

### **Advancements in Treatment Technologies**

Technological advancements in medical treatments, particularly in prostate cancer, are fostering growth in the US Prostate Cancer Treatment Market Industry. Recent developments in precision medicine, robot-assisted surgeries, and improved radiation techniques have led to better patient outcomes. For instance, a report from the U.S. Food and Drug Administration indicates an increase in approved therapies for prostate cancer, reflecting the commitment to innovative research and the introduction of new treatment modalities.

The National Institutes of Health also focuses substantial funding on Research and Development for prostate cancer, aligning with the industry's push for state-of-the-art solutions that cater to the individualized needs of patients. This trend is likely to accelerate the adoption and expansion of effective treatment options, enhancing overall market potential.

### **Aging Population and Increased Healthcare Spending**

The demographic shift towards an aging population in the United States significantly impacts the US Prostate Cancer Treatment Market Industry. According to the U.S. Census Bureau, the population aged 65 and older is projected to reach 94.7 million by 2060, up from 52 million in 2018. This demographic is at an increased risk of developing prostate cancer, leading to a higher demand for treatments. Furthermore, increasing healthcare spending in the U.S.

is driving this market forward. The Centers for Medicare & Medicaid Services reported that national health expenditure is projected to grow at an average rate of 5.4% per year from 2019 to 2028, indicating a strong financial commitment to healthcare, including cancer treatment. This trend supports a robust market environment conducive to growth in the prostate cancer treatment segment.

### **Growing Awareness and Government Initiatives**

Heightened awareness about prostate cancer through national campaigns and government initiatives is propelling the US Prostate Cancer Treatment Market Industry. The National Cancer Institute, through its ongoing education programs, has been pivotal in increasing public understanding of prostate cancer risks, early detection, and treatment options. Coupled with federal initiatives like the Cancer Moonshot Program aimed at accelerating cancer research, these efforts are essential in encouraging men to engage in routine screenings.

According to the CDC, nearly 20% of the prostate cancer cases are diagnosed at an advanced stage; thus, increasing awareness can potentially change this statistic, leading to more men seeking treatments early on. This focus on education and advocacy is critically contributing to market growth by ensuring higher engagement from the affected populations.

## **US Prostate Cancer Treatment Market Segment Insights**

### **Prostate Cancer Treatment Market Treatment Type Insights**

The Treatment Type segment of the US Prostate Cancer Treatment Market encompasses diverse approaches tailored for optimal patient outcomes. Surgery remains a pivotal intervention, with techniques evolving significantly over recent years, contributing to reduced recovery times and improved prognosis. Radiation therapy, in various forms, plays a vital role and is favored for its ability to target cancer cells precisely while minimizing damage to surrounding healthy tissues, often being a preferred choice when surgery is not viable.

Hormonal therapy is important as it effectively manages advanced prostate cancer by manipulating hormones that fuel cancer growth, thereby extending patient survival and enhancing quality of life.

[Chemotherapy](../../../reports/chemotherapy-market-5791), while traditionally associated with aggressive cancer forms, is increasingly integrated as a complement to other therapies, showcasing efficacy in more advanced stages where other treatments may fall short. Immunotherapy represents an exciting frontier in the treatment landscape by harnessing the body's immune system to combat cancer cells, demonstrating promise especially in patients who have not responded to standard therapies. The growth in the US Prostate Cancer Treatment Market is supported by an increasing awareness of prostate health, advancements in treatment technologies, and a growing aging population that is more susceptible to prostate cancer.

The market thrives on innovation, with ongoing research aimed at optimizing these treatment modalities, focusing particularly on reducing side effects and improving outcomes. As medical professionals increasingly tailor treatment plans based on individual patient profiles, understanding the nuances within this segment will be crucial for stakeholders aiming to navigate the complex landscape of the US Prostate Cancer Treatment Market. With new therapeutic options on the horizon, the Treatment Type segment is expected to evolve, addressing unmet needs and improving overall patient care in this critical space.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Prostate Cancer Treatment Market Administration Route Insights**

The Administration Route segment of the US Prostate Cancer Treatment Market plays a crucial role in delivering effective therapy options to patients. This segment encompasses various methods, including Oral, Injection, Intravenous, and Topical therapies, each with its significance in treatment administration. Oral medications offer convenience and compliance, appealing to patients seeking less invasive options. On the other hand, Injection and Intravenous routes are often favored for their rapid onset of action and precise dosage control, essential in managing aggressive forms of prostate cancer.

The Topical administration route provides localized treatment solutions, making it an important choice for specific cases. The continuous advancement in drug formulations and delivery mechanisms enhances patient accessibility and enhances outcomes, aligning with trends towards personalized medicine in the US. The population aging and rising awareness regarding prostate cancer treatment are critical growth drivers, while challenges such as side effects and patient adherence remain prevalent. Overall, this segment is a vital component in the management of prostate cancer, contributing significantly to the US Prostate Cancer Treatment Market statistics.

### **Prostate Cancer Treatment Market End Users Insights**

The End Users segment of the US Prostate Cancer Treatment Market displays a diverse landscape comprised of Hospitals, Clinics, Homecare, and Research Institutions. Hospitals are pivotal as they offer comprehensive treatment options and advanced technologies, making them a major player in delivering care. Clinics contribute significantly by providing focused treatments and follow-up care tailored to individual needs, enhancing patient convenience. Homecare has seen a surge in demand, reflecting a trend toward outpatient services and patient-centric care, particularly as more individuals prefer the comfort of receiving treatment in their own homes.

Research Institutions play a crucial role in advancing understanding and innovation in prostate cancer therapies, driving development and adoption of new treatments. The interplay among these entities is indicative of a collaborative environment that aims to improve patient outcomes and streamline care delivery within the US Prostate Cancer Treatment Market ecosystem. As the population ages and the prevalence of prostate cancer rises, the importance of these end users in shaping market dynamics becomes increasingly pronounced.

### **Prostate Cancer Treatment Market Disease Stage Insights**

The US Prostate Cancer Treatment Market has a significant focus on the Disease Stage segment, which includes Localized, Locally Advanced, and Metastatic stages. Localized prostate cancer, where the disease is confined within the prostate gland, represents a crucial area for the treatment landscape. This group often sees effective management options such as surgery and radiation therapy, which are essential for patient outcomes. The Locally Advanced stage, characterized by the cancer extending beyond the prostate but not to distant organs, highlights the need for more aggressive treatment protocols, including hormone therapy and combined modalities.

This stage is vital as it requires multi-faceted treatment approaches to prevent progression. Metastatic prostate cancer, where the cancer has spread to other body parts, poses significant treatment challenges, necessitating ongoing Research and Development for new therapies. This distinction into various stages reflects the importance of tailored treatment plans that adapt to the specific needs of patients at different points in their disease progression. Understanding these segments is critical for healthcare providers to ensure effective patient management and for stakeholders to pinpoint areas for growth in the US Prostate Cancer Treatment Market.

Overall, the segmentation emphasizes different strategies tailored to the intricacies of the disease, driving innovation and improving patient care outcomes in the US.

## **US Prostate Cancer Treatment Market Key Players and Competitive Insights**

The US Prostate Cancer Treatment Market is characterized by a dynamic and competitive landscape driven by advancements in medical technology, research, and increasing awareness of prostate cancer treatment options among healthcare professionals and patients alike. Prostate cancer, being one of the most prevalent cancers among men in the United States, has fostered a varied range of treatment modalities, including hormone therapy, immunotherapy, chemotherapy, and targeted therapies.

The market is not only impacted by the growing aging population, which sees a rise in prostate cancer incidences, but also by ongoing innovations in pharmaceutical and biotechnology sectors that are introducing new therapies and improved treatment protocols. Companies within this market are striving to enhance their portfolios through research and collaborations, capturing market share and ensuring sustained growth in a competitive environment.

Sanofi has established a significant presence in the US Prostate Cancer Treatment Market primarily through its robust portfolio of pharmaceutical products aimed at addressing cancer care. The company's strong brand reputation, comprehensive research capabilities, and commitment to innovative therapeutic solutions contribute to its competitive edge. Sanofi emphasizes its role in raising awareness about prostate cancer and advocating for early detection and treatment among healthcare providers and patients. The company’s strategic investments in clinical research to understand prostate cancer better and develop effective treatment options have fortified its position in the market.

Moreover, Sanofi's collaborations and partnerships with other entities in healthcare, along with its efforts in expanding access to life-saving treatments, further enhance its standing in this critical area of cancer care.

Bayer also plays a pivotal role in the US Prostate Cancer Treatment Market, with a well-defined portfolio that includes key therapeutic products specifically designed for prostate cancer. Its focus on innovative treatments is complemented by a commitment to research and development, allowing Bayer to quickly adapt to the evolving needs of the market. The company’s flagship products serve as crucial components in prostate cancer management, underscoring Bayer's influence in improving patient outcomes. Bayer has also made significant strides in expanding its market presence through strategic mergers and acquisitions, fostering synergies that enhance its capabilities and service offerings.

The company actively invests in clinical trials and research aimed at discovering emerging therapies for prostate cancer, reinforcing its dedication to addressing this unmet medical need in the US. Bayer’s integrated approach to healthcare solutions positions favorably within the competitive landscape, enabling the company to respond effectively to the demands of patients and healthcare providers alike.

### **Key Companies in the US Prostate Cancer Treatment Market Include**

### **US Prostate Cancer Treatment Market Industry Developments**

The US Prostate Cancer Treatment Market has recently experienced several pivotal developments. In October 2023, Pfizer and Astellas Pharma announced the initiation of a collaborative phase 3 trial to evaluate a new combination therapy for advanced prostate cancer, emphasizing their commitment to innovation in treatment options. Additionally, Johnson and Johnson reported encouraging results from their latest clinical trial involving a prostate cancer immunotherapy treatment that showed increased survival rates. In terms of market valuation, AbbVie has seen significant growth in stock prices following the successful launch of their latest prostate cancer treatment, greatly impacting the competitive landscape.

Furthermore, in August 2023, Bayer completed its acquisition of a biotech firm specializing in prostate cancer therapies, bolstering its portfolio in this therapeutic area. This move aligns with the recent trend of mergers and acquisitions among major players like Exelixis and Merck and Company, as companies seek to expand their research and treatment capabilities. Overall, advancements in clinical research, strategic partnerships, and market expansions are currently shaping the US Prostate Cancer Treatment Market, reflecting a dynamic and rapidly evolving landscape.

## **Prostate Cancer Treatment Market Segmentation Insights**

### **Prostate Cancer Treatment Market Treatment Type Outlook**

### **Prostate Cancer Treatment Market Administration Route Outlook**

### **Prostate Cancer Treatment Market End Users Outlook**

### **Prostate Cancer Treatment Market Disease Stage Outlook**

## Market Drivers

### Emergence of Personalized Medicine

The prostate cancer-treatment market is increasingly shaped by the emergence of personalized medicine, which tailors treatment strategies to individual patient profiles. Advances in genomics and molecular biology enable healthcare providers to identify specific genetic mutations associated with prostate cancer, allowing for more targeted therapies. This approach not only improves treatment efficacy but also minimizes adverse effects, enhancing the overall patient experience. The market for personalized medicine in oncology is projected to grow at a CAGR of 10% through 2028, indicating a strong trend towards individualized treatment plans. As more healthcare providers adopt personalized medicine practices, the prostate cancer-treatment market is likely to expand, reflecting a shift towards more effective and patient-centered care.

### Rising Incidence of Prostate Cancer

The prostate cancer-treatment market is significantly influenced by the rising incidence of prostate cancer among men in the United States. According to the American Cancer Society, approximately 1 in 8 men will be diagnosed with prostate cancer during their lifetime. This increasing prevalence is driving demand for various treatment options, including surgery, radiation therapy, and hormone therapy. The market is projected to reach a valuation of $20 billion by 2026, reflecting the urgent need for effective treatment solutions. As awareness of prostate cancer grows, coupled with improved screening practices, the number of diagnosed cases is expected to rise, further propelling the prostate cancer-treatment market. This trend underscores the necessity for ongoing research and development in treatment modalities to address the needs of an expanding patient population.

### Advancements in Diagnostic Technologies

The prostate cancer-treatment market is experiencing a notable shift due to advancements in diagnostic technologies. Innovations such as MRI-targeted biopsies and liquid biopsies enhance the accuracy of prostate cancer detection. These technologies allow for earlier diagnosis, which is crucial for effective treatment. The market for diagnostic imaging is projected to grow at a CAGR of approximately 8% through 2027, indicating a robust demand for improved diagnostic tools. Enhanced diagnostic capabilities not only facilitate timely interventions but also contribute to personalized treatment plans, thereby improving patient outcomes. As a result, the integration of advanced diagnostic technologies is likely to drive growth in the prostate cancer-treatment market, as healthcare providers increasingly adopt these tools to optimize patient care.

### Increased Investment in Cancer Research

The prostate cancer-treatment market is benefiting from increased investment in cancer research, which is crucial for developing new therapies and improving existing treatment options. Government funding and private sector investments are on the rise, with the National Cancer Institute allocating over $5 billion annually for cancer research initiatives. This financial support fosters innovation in treatment approaches, including targeted therapies and immunotherapies. As new findings emerge from research, they are likely to translate into more effective treatment protocols, enhancing patient outcomes. The influx of capital into cancer research not only stimulates advancements in the prostate cancer-treatment market but also encourages collaboration between academic institutions and pharmaceutical companies, potentially leading to breakthroughs in treatment.

### Growing Awareness and Education Initiatives

The prostate cancer-treatment market is experiencing growth due to increasing awareness and education initiatives aimed at men regarding prostate health. Campaigns by organizations such as the Prostate Cancer Foundation are instrumental in disseminating information about risk factors, screening, and treatment options. As awareness rises, more men are seeking medical advice and screening, leading to earlier detection and treatment. This trend is reflected in the increased number of prostate-specific antigen (PSA) tests conducted annually, which has seen a rise of approximately 15% over the past five years. Enhanced public knowledge about prostate cancer is likely to drive demand for treatment options, thereby positively impacting the prostate cancer-treatment market.

## Future Outlook

The [Prostate Cancer Treatment Market](https://www.marketresearchfuture.com/reports/prostate-cancer-treatment-market-21330) is projected to grow at a 5.21% CAGR from 2025 to 2035, driven by advancements in therapies, increasing awareness, and rising incidence rates.

**New opportunities:**

- Development of personalized medicine solutions for targeted therapies. Expansion of telehealth services for remote patient monitoring. Investment in AI-driven diagnostic tools to enhance early detection.

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient access.

## Segment Insights

### By Type: Surgery (Largest) vs. Immunotherapy (Fastest-Growing)

In the US prostate cancer-treatment market, the distribution of market share among treatment types shows Surgery as the largest segment, capturing a significant portion of the market due to its established efficacy and acceptance among healthcare professionals. Radiation Therapy and Hormonal Therapy follow, offering effective alternatives for specific patient profiles, while Chemotherapy and Immunotherapy remain smaller segments, though growing in importance as new treatments emerge.

Growth trends in the US prostate cancer-treatment market reflect a shift towards more personalized treatment options, with Immunotherapy rapidly gaining traction as the fastest-growing segment. Increasing clinical evidence supporting its effectiveness and advancements in technology have driven this growth. The demand for tailored therapies is also propelling the acceptance of Hormonal and Chemotherapy treatments, enhancing the competitive landscape of the market.

Surgery (Dominant) vs. Immunotherapy (Emerging)

Surgery, particularly radical prostatectomy, has established itself as the dominant approach in the US prostate cancer-treatment market due to its direct removal of cancerous tissues and associated survival benefits. This method is often preferred for patients with localized cancer and has a long-standing history of clinical success. Conversely, Immunotherapy is emerging as a promising option, especially for advanced cases. This approach leverages the body’s immune system to target cancer cells, showcasing significant potential for patients who have not responded well to traditional therapies. With ongoing research and clinical trials, Immunotherapy is anticipated to carve its niche within the treatment landscape, reflecting a shift towards innovative treatment modalities that personalize patient care.

### By Administration Route: Injection (Largest) vs. Oral (Fastest-Growing)

In the US prostate cancer-treatment market, the administration route segment is diverse, encompassing oral, injection, intravenous, and topical methods. Currently, injection-based therapies hold the largest market share, attributed to their effectiveness and established usage in clinical settings. Meanwhile, oral therapies have rapidly gained traction, appealing to patients' preferences for convenience and ease of administration. As such, this segment is characterized by a dynamic interplay between traditional methods and emerging alternatives.

Growth trends indicate a shift towards oral ingestion methods, highlighting the rising demand for patient-friendly treatment options. The increasing prevalence of prostate cancer, combined with innovations in drug formulations, drives the expansion of oral therapies, while injections remain essential, particularly for advanced cases requiring immediate therapeutic intervention. This evolving landscape demonstrates the need for continuous adaptation in treatment options to meet patient needs and preferences.

Injection (Dominant) vs. Oral (Emerging)

Injection therapies play a dominant role in the US prostate cancer-treatment market due to their proven efficacy and reliability in delivering medications directly into the bloodstream. This method is particularly favored in urgent treatment scenarios and for patients requiring potent formulations that provide rapid results. On the other hand, oral therapies are emerging rapidly, characterized by their ease of use and preference among patients for non-invasive options. The development of advanced oral formulations has significantly enhanced drug absorption and bioavailability, making them a competitive alternative to traditional injections. Both methods showcase the market's adaptation to patient needs, with injections offering immediate action and oral medications providing a more patient-centric approach.

### By End Users: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the US prostate cancer-treatment market, hospitals represent the largest segment, with a significant percentage of total market engagement. They are preferred for their advanced treatment options and comprehensive care services that cater to patients needing specialized attention. Clinics, meanwhile, are emerging as a vital segment in the market, with their share steadily increasing due to the convenience they offer and the growing preference for outpatient services, making them a competitive player.

Growth trends indicate that while hospitals maintain dominance, clinics are evolving rapidly, driven by advancements in technology and increased patient demand for personalized care solutions. Homecare services are also contributing to the market, providing flexibility and comfort for patients. Research institutions play a pivotal role in driving innovation, which further propels the competition among these segments as they seek to improve treatment outcomes.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals dominate the US prostate cancer-treatment market by offering comprehensive cancer care, from diagnosis to advanced treatment options. They are equipped with the latest medical technologies and staffed by specialists who provide tailored therapies including surgery, radiation, and chemotherapy. This institutional strength positions hospitals as the go-to choice for patients seeking direct medical intervention. In contrast, clinics are emerging as a significant alternative, primarily catering to patients who prefer less invasive treatments and outpatient care. Their growth is bolstered by a shift in patient preferences, as they offer convenient service and focus on preventative care, often featuring a more accessible approach to initial screenings and minor procedures. This dynamic creates a competitive landscape between hospitals and clinics, where each serves distinct yet overlapping patient needs.

### By Disease Stage: Localized (Largest) vs. Metastatic (Fastest-Growing)

In the US prostate cancer-treatment market, the market share distribution among disease stages indicates that the Localized stage occupies the largest share. Patients diagnosed at this stage typically reflect a stable and manageable condition, leading to a significant preference for treatments that aim for a cure, thereby creating a robust segment within the overall market. On the other hand, the Metastatic stage, though smaller in size, is experiencing rapid growth as advanced treatment options gain traction, resulting in increased demand.

Growth trends show a clear divide between the Localized and Metastatic segments. The Localized stage's dominance is driven by early detection methods and increasing awareness among patients regarding treatment options. Conversely, the Metastatic stage is expanding swiftly due to breakthroughs in therapies, clinical trials showing promising outcomes, and a growing aging population that may face advanced cases. These dynamics showcase divergent performance trends across the stages, with ongoing innovation further bolstering growth.

Localized (Dominant) vs. Metastatic (Emerging)

The Localized stage is characterized by earlier intervention opportunities, leading to a higher success rate with various treatment modalities. Patients in this stage often have a wide range of options including surgery and radiation, contributing to its dominant position in the market. As healthcare providers emphasize early detection through screenings, the awareness and treatment for Localized prostate cancer continue to thrive. Conversely, the Metastatic stage, presenting a more challenging clinical scenario, represents an emerging growth area due to increased investments in novel therapeutic approaches. With advancements in immunotherapy and targeted treatments, the Metastatic segment is seeing heightened interest from both healthcare providers and patients seeking effective management solutions. This duality in stage dynamics marks the evolving landscape of the US prostate cancer-treatment market.

## Competitive Benchmarking

The prostate cancer-treatment market is characterized by a dynamic competitive landscape, driven by advancements in therapeutic options and increasing prevalence of the disease. Key players such as Johnson & Johnson (US), Merck & Co (US), and Astellas Pharma (JP) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Johnson & Johnson (US) focuses on expanding its oncology portfolio through strategic acquisitions and collaborations, while Merck & Co (US) emphasizes research and development to introduce novel therapies. Astellas Pharma (JP) is actively pursuing regional expansion and digital transformation initiatives to optimize its operational efficiency and patient engagement. The market structure appears moderately fragmented, with several players vying for market share. Companies are adopting various business tactics, including localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. This collective influence of key players fosters a competitive environment where innovation and operational excellence are paramount. In October 2025, Merck & Co (US) announced a collaboration with a leading biotechnology firm to develop a new immunotherapy for advanced prostate cancer. This strategic move is likely to enhance Merck's position in the market by diversifying its treatment options and addressing unmet medical needs. The collaboration underscores the importance of innovation in driving competitive advantage in the prostate cancer-treatment landscape. In September 2025, Johnson & Johnson (US) launched a new digital platform aimed at improving patient access to its prostate cancer therapies. This initiative reflects the company's commitment to enhancing patient engagement and streamlining the treatment journey. By integrating digital solutions, Johnson & Johnson (US) may strengthen its market position and foster loyalty among healthcare providers and patients alike. In August 2025, Astellas Pharma (JP) expanded its partnership with a prominent research institution to explore novel biomarkers for prostate cancer treatment response. This strategic action indicates Astellas' focus on precision medicine and personalized treatment approaches, which could potentially lead to improved patient outcomes and a competitive edge in the market. As of November 2025, current trends in the prostate cancer-treatment market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, positioning companies to better meet the needs of patients and healthcare providers.

## Recent News & Developments

The US Prostate Cancer Treatment Market has recently experienced several pivotal developments. In October 2023, Pfizer and Astellas Pharma announced the initiation of a collaborative phase 3 trial to evaluate a new combination therapy for advanced prostate cancer, emphasizing their commitment to innovation in treatment options. Additionally, Johnson and Johnson reported encouraging results from their latest clinical trial involving a prostate cancer immunotherapy treatment that showed increased survival rates. In terms of market valuation, AbbVie has seen significant growth in stock prices following the successful launch of their latest prostate cancer treatment, greatly impacting the competitive landscape.

Furthermore, in August 2023, Bayer completed its acquisition of a biotech firm specializing in prostate cancer therapies, bolstering its portfolio in this therapeutic area. This move aligns with the recent trend of mergers and acquisitions among major players like Exelixis and Merck and Company, as companies seek to expand their research and treatment capabilities. Overall, advancements in clinical research, strategic partnerships, and market expansions are currently shaping the US Prostate Cancer Treatment Market, reflecting a dynamic and rapidly evolving landscape.

## Report Scope

| MARKET SIZE 2024 | 2181.64(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2295.3(USD Million) |
| MARKET SIZE 2035 | 3814.9(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.21% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Astellas Pharma (JP), Bayer AG (DE), Johnson & Johnson (US), Pfizer Inc (US), Merck & Co (US), Novartis AG (CH), Sanofi (FR), Ipsen S.A. (FR) |
| Segments Covered | Type, Administration Route, End Users, Disease Stage |
| Key Market Opportunities | Advancements in immunotherapy and personalized medicine enhance treatment options in the prostate cancer-treatment market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in prostate cancer treatment options and patient accessibility. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US prostate cancer-treatment market in 2024?**
A: The overall market valuation was $2181.64 Million in 2024.

**Q: What is the projected market valuation for the US prostate cancer-treatment market by 2035?**
A: The projected valuation for 2035 is $3814.9 Million.

**Q: What is the expected CAGR for the US prostate cancer-treatment market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 5.21%.

**Q: Which companies are considered key players in the US prostate cancer-treatment market?**
A: Key players include Astellas Pharma, Bayer AG, Johnson & Johnson, Pfizer Inc, Merck & Co, Novartis AG, Sanofi, and Ipsen S.A.

**Q: What were the revenue ranges for surgery in the US prostate cancer-treatment market?**
A: The revenue range for surgery was between $500.0 Million and $850.0 Million.

**Q: How much revenue did radiation therapy generate in the US prostate cancer-treatment market?**
A: Radiation therapy generated revenue between $600.0 Million and $1000.0 Million.

**Q: What is the revenue range for hormonal therapy in the US prostate cancer-treatment market?**
A: The revenue range for hormonal therapy is between $700.0 Million and $1200.0 Million.

**Q: What are the revenue figures for chemotherapy in the US prostate cancer-treatment market?**
A: Chemotherapy generated revenue between $300.0 Million and $500.0 Million.

**Q: What is the projected revenue for immunotherapy in the US prostate cancer-treatment market?**
A: The projected revenue for immunotherapy ranges from $81.64 Million to $264.9 Million.

**Q: What are the revenue ranges for the end users of the US prostate cancer-treatment market?**
A: End user revenue ranges include hospitals at $1090.82 Million to $1890.45 Million, clinics at $655.0 Million to $1130.0 Million, homecare at $327.5 Million to $570.0 Million, and research institutions at $108.32 Million to $224.45 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-prostate-cancer-treatment-market-52774*